In This Section

CICR at the Annual Meeting

 

Virtual Meeting
Week 1: April 10-15; Week 2: May 17-21

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.

DDT03. New Drugs on the Horizon: Part 1

Saturday, April 10, 2021, 1:30 pm – 3:15 pm
Channel 01
This is one of three Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia. These sessions offer the opportunity for Annual Meeting attendees to see the first disclosures of twelve innovative agents, both small molecules and biologics that have recently entered, or imminently will enter, into phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical or biologic structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans. The New Drugs on the Horizon sessions have always proven to be an excellent opportunity to learn about the next wave of innovative cancer drugs progressing in the clinic.

Chairperson Andrew J. Phillips. Cormorant Asset Management, LLC, Boston, MA
Chairperson James E. Audia. Northwestern University – Evanston, Chicago, IL
Liangxing Wu. Incyte Corporation, Wilmington, DE
Nicholas J. Keen. Bicycle Therapeutics, Lexington, MA
Pablo Umana. Roche Glycart AG, Schlieren, Switzerland
Travis Young. Scripps Research Institute, La Jolla, CA

DDT01. New Drugs on the Horizon: Part 2

Saturday, April 10, 2021, 4:00 pm – 5:45 pm
Channel 01
This is one of three Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia. These sessions offer the opportunity for Annual Meeting attendees to see the first disclosures of twelve innovative agents, both small molecules and biologics that have recently entered, or imminently will enter, into phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical or biologic structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans. The New Drugs on the Horizon sessions have always proven to be an excellent opportunity to learn about the next wave of innovative cancer drugs progressing in the clinic.

Chairperson Philip Jones. UT MD Anderson Cancer Center, Houston, TX
Chairperson Chudi Ndubaku. ORIC Pharmaceuticals, South San Francisco, CA
Elisabetta Leo. AstraZeneca Oncology, Cambridge, United Kingdom
David Dornan. Bolt Biotherapeutics, Redwood City, CA
Jenny Karlsson. Bayer US Healthcare, Oslo, Norway
Theresa Kolben. F. Hoffmann-La Roche Ltd., Penzberg, Germany

DDT02. New Drugs on the Horizon: Part 3

Monday, April 12, 2021, 1:30 pm – 3:15 pm
Channel 02
This is one of three Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia. These sessions offer the opportunity for Annual Meeting attendees to see the first disclosures of twelve innovative agents, both small molecules and biologics that have recently entered, or imminently will enter, into phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical or biologic structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans. The New Drugs on the Horizon sessions have always proven to be an excellent opportunity to learn about the next wave of innovative cancer drugs progressing in the clinic.

Chairperson Joachim Rudolph. Genentech, Inc., South San Francisco, CA
Chairperson Laura Akullian D’Agostino. Bristol-Myers Squibb, Cambridge, MA
Robert L. Hoffman. Pfizer Global Research & Development, San Diego, CA
G. Leslie Burnett. Revolution Medicines, Inc., Redwood City, CA
A. Robert Macleod. Ionis Pharmaceuticals Inc., Carlsbad, CA

TM01. Chemistry in Cancer Research Working Group (CICR) Town Hall Meeting

Monday, May 17, 2021, 3:30 pm – 5:00 pm
CICR Chair Philip Jones. UT MD Anderson Cancer Center, Houston, TX
CICR Chair-Elect Joachim Rudolph. Genentech, Inc., South San Francisco, CA

Be sure to watch the AACR Award for Outstanding Achievement in Chemistry in Cancer Research on demand starting April 10th on our online meeting platform.

See more on the online meeting planner.